Breaking News Instant updates and real-time market news.

ARWR

Arrowhead

$4.39

-0.07 (-1.57%)

, AMGN

Amgen

$146.00

0.93 (0.64%)

16:12
11/29/16
11/29
16:12
11/29/16
16:12

Arrowhead to halt development of all EX1 programs, cut 30% of workforce

Arrowhead Pharmaceuticals (ARWR) announced a "strategic redeployment" of resources to support the development of RNAi therapeutics that utilize the company's new proprietary subcutaneous and extra-hepatic delivery systems. Arrowhead will discontinue development of clinical stage drug candidates ARC-520, ARC-521, and ARC-AAT, which utilize the DPCiv, or EX1, delivery vehicle. "Arrowhead remains committed to finding therapeutic options for patients with chronic hepatitis B infection and alpha-1 antitrypsin deficiency. The company intends to advance to the clinic two previously unannounced HBV and AATD programs using our subQ platform. Arrowhead has learned a great deal during prior HBV and AAT studies that will help drive the subQ programs efficiently. Existing preclinical subQ and extra-hepatic programs such as ARC-LPA and ARC-AMG1, which are partnered with Amgen (AMGN), ARC-F12, ARC-HIF2, and other unannounced programs are not affected by this decision," it said. The company is reducing its workforce by approximately 30%, while "maintaining full resourcing necessary to support current and potential future partner-based programs and Arrowhead's burgeoning pipeline." This structure should enable the company to continue to "develop its programs rapidly," and is intended to extend its cash runway into 2019. The company further noted: "The decision to discontinue development of EX1-containing programs was based primarily on two factors. First, during ongoing discussions with regulatory agencies and outside experts, it became apparent that there would be substantial delays in all clinical programs that utilize EX1, while the company further explored the cause of deaths in a non-clinical toxicology study in non-human primates. Second, Arrowhead has made substantial advances in RNA chemistry and targeting resulting in large potency gains for subQ administered and extra-hepatic RNAi-based development programs. In preclinical studies with the subQ platform, the company has obtained depth and duration of target gene knockdown approaching that of intravenously administered EX1-containing candidates, at lower doses and with good safety margins... In addition, across the ARC-520, ARC-521, and ARC-AAT clinical programs, laboratory values have not been deemed indicative of drug induced organ toxicity."

ARWR

Arrowhead

$4.39

-0.07 (-1.57%)

AMGN

Amgen

$146.00

0.93 (0.64%)

  • 29

    Nov

  • 29

    Nov

  • 19

    Jul

ARWR Arrowhead
$4.39

-0.07 (-1.57%)

10/06/16
RBCM
10/06/16
NO CHANGE
RBCM
Alnylam news not a negative read through on other RNAi drugs, says RBC Capital
After Alnylam (ALNY) announced that it was discontinuing one of its Phase III RNAi drugs due to poor clinical outcomes, RBC Capital analyst Michael Yee does not thinks that the news indicates problems with all RNAi drugs. Rather, he thinks that RNAi was not the proper treatment for the disease that Alnylam was targeting. Other companies with RNAi treatments include The Medicines Company (MDCO0, Ionis Pharmaceuticals (IONS), Arrowhead (ARWR), and Arbutus Biopharma (ABUS).
09/29/16
PIPR
09/29/16
NO CHANGE
Target $10
PIPR
Overweight
Arrowhead price target raised to $10 from $8 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead Pharmaceuticals (ARWR) to $10 after the company licensed two preclinical cardiovascular RNAi drugs with Amgen (AMGN). Amgen is the "ideal partner" and Arrowhead's balance sheet is now "meaningfully" strengthened, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Arrowhead.
08/19/16
WBLR
08/19/16
INITIATION
Target $9
WBLR
Outperform
Arrowhead initiated with an Outperform at William Blair
William Blair analyst Y. Katherine Xu started Arrowhead Pharmaceuticals with an Outperform rating and $9 price target.
08/18/16
08/18/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Barnes & Noble (BKS) initiated with a Neutral at Sidoti. 2. Digital Ally (DGLY) initiated with a Buy at Maxim. 3. Korn/Ferry (KFY) initiated with a Hold at Deutsche Bank. 4. Phillips 66 Partners (PSXP) initiated with a Buy at Stifel. 5. Arrowhead (ARWR) initiated with a Buy at Cantor. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
AMGN Amgen
$146.00

0.93 (0.64%)

11/09/16
PIPR
11/09/16
NO CHANGE
PIPR
Piper sees improving environment for Biopharma M&A
The biotech sector is seeing a "massive relief rally" given the "surprise trifecta" of a Republican sweep, the voting down of Prop 61 in California and U.S. dollar weakness, Piper Jaffray analyst Joshua Schimmer tells investors in a research note. The door is now open to discuss potential repatriation of cash outside the U.S., which could be a green light on mergers and acquisitions, the analyst adds. He points out that Amgen (AMGN) and Gilead (GILD) hold the most overseas cash, with Celgene (CELG) and Biogen (BIIB) holding several billion as well. Schimmer believes the broader environment may be improving for M&A. He cautions, though, that the election of Trump does not remove the "major drug pricing overhang question."
11/08/16
11/08/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Adient (ADNT) initiated with a Neutral at JPMorgan. 2. JinkoSolar (JKS) initiated with a Buy at Craig-Hallum. 3. Amgen (AMGN), Gilead (GILD), and Celgene (CELG) initiated with a Buy at Mizuho while the firm initiated Biogen (BIIB) with a Neutral. 4. BioScrip (BIOS) resumed with a Buy at Jefferies. 5. SQM (SQM) initiated with a Market Perform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/08/16
ARGS
11/08/16
NO CHANGE
ARGS
Amgen weakness creates buying opportunity, says Argus
After Amgen's stock sunk 10% following its Q3 results, Argus says that the decline was triggered by "news that pricing power for Enbrel would be limited in 2017." However, the firm says that the company's growth outlook is "solid," while it has launched "promising new drugs." The firm keeps a Buy rating on the stock.
11/07/16
MZHO
11/07/16
INITIATION
Target $164
MZHO
Buy
Amgen initiated with a Buy at Mizuho
Mizuho analyst Salim Syed initiated Amgen with a Buy rating and a $164 price target.

TODAY'S FREE FLY STORIES

HCLP

Hi-Crush Partners

$22.97

1.5705 (7.34%)

12:26
02/22/17
02/22
12:26
02/22/17
12:26
Upgrade
Hi-Crush Partners rating change  »

Wunderlich upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Feb

PAA

Plains All American

$30.57

-0.67 (-2.14%)

12:26
02/22/17
02/22
12:26
02/22/17
12:26
Options
Plains All American call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 08

    Aug

  • 08

    Nov

12:25
02/22/17
02/22
12:25
02/22/17
12:25
General news
Euro$ interest rate futures stalled out »

Euro$ interest rate…

12:25
02/22/17
02/22
12:25
02/22/17
12:25
Conference/Events
Forecasters Club of New York to hold a luncheon meeting »

Federal Reserve Governor…

USPH

U.S. Physical Therapy

$74.55

-1.55 (-2.04%)

12:25
02/22/17
02/22
12:25
02/22/17
12:25
Conference/Events
CFA Society of Houston to hold a luncheon meeting »

Chris Reading, CEO of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 21

    Mar

  • 29

    Mar

  • 11

    Apr

  • 12

    Apr

PUGOY

Peugeot

$19.40

-0.215 (-1.10%)

, GM

General Motors

$37.86

0.05 (0.13%)

12:23
02/22/17
02/22
12:23
02/22/17
12:23
Periodicals
PSA Group targets up to $2.1B in cost savings from Opel deal, Reuters says »

Peugeot (PUGOY) parent…

PUGOY

Peugeot

$19.40

-0.215 (-1.10%)

GM

General Motors

$37.86

0.05 (0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

SCOR

comScore

$24.42

0.12 (0.49%)

12:21
02/22/17
02/22
12:21
02/22/17
12:21
Conference/Events
comScore to host business news update conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 24

    Feb

BA

Boeing

$175.52

-0.04 (-0.02%)

, LMT

Lockheed Martin

$264.87

-0.79 (-0.30%)

12:19
02/22/17
02/22
12:19
02/22/17
12:19
Periodicals
Key lawmaker: Trump jet competition 'doesn't make sense,' Bloomberg reports »

Speaking in a Bloomberg…

BA

Boeing

$175.52

-0.04 (-0.02%)

LMT

Lockheed Martin

$264.87

-0.79 (-0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

$NSD

NASDAQ Market Internals

12:17
02/22/17
02/22
12:17
02/22/17
12:17
Technical Analysis
NASDAQ Market Internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:17
02/22/17
02/22
12:17
02/22/17
12:17
Technical Analysis
NYSE Market Internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$119.46

-0.2 (-0.17%)

12:17
02/22/17
02/22
12:17
02/22/17
12:17
Conference/Events
Johnson & Johnson hs a conference call hosted by JPMorgan »

JPMorgan Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 24

    Feb

  • 09

    Mar

  • 14

    Mar

  • 27

    Mar

12:15
02/22/17
02/22
12:15
02/22/17
12:15
General news
FX Action: USD-JPY »

FX Action: USD-JPY traded…

UN

Unilever; also tag UL

$46.74

1.65 (3.66%)

, UL

Unilever; also tag UN

$46.99

2.12 (4.72%)

12:14
02/22/17
02/22
12:14
02/22/17
12:14
General news
On The Fly: Top stock stories at midday »

Stocks opened in negative…

UN

Unilever; also tag UL

$46.74

1.65 (3.66%)

UL

Unilever; also tag UN

$46.99

2.12 (4.72%)

KHC

Kraft Heinz

$94.87

-1.78 (-1.84%)

TJX

TJX

$76.00

-0.245 (-0.32%)

GRMN

Garmin

$50.45

-0.36 (-0.71%)

TOL

Toll Brothers

$34.04

2.05 (6.41%)

DEPO

Depomed

$15.77

-0.7 (-4.25%)

CHS

Chico's

$14.93

0.635 (4.44%)

PZZA

Papa John's

$85.63

-0.38 (-0.44%)

TXRH

Texas Roadhouse

$47.79

-0.45 (-0.93%)

FSLR

First Solar

$36.62

1.78 (5.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 27

    Feb

  • 28

    Feb

  • 01

    Mar

  • 19

    Mar

INGIY

Ingenico

$16.94

0.02 (0.12%)

12:06
02/22/17
02/22
12:06
02/22/17
12:06
Hot Stocks
Ingenico finalizes acquisition of TechProcess; terms not disclosed »

Ingenico Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

HCLP

Hi-Crush Partners

$23.05

1.65 (7.71%)

12:06
02/22/17
02/22
12:06
02/22/17
12:06
Upgrade
Hi-Crush Partners rating change  »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Feb

12:05
02/22/17
02/22
12:05
02/22/17
12:05
General news
Treasury's $13 B 2-year FRN reopening was mixed »

Treasury's $13 B…

NFX

Newfield Exploration

$39.62

-2.87 (-6.75%)

12:01
02/22/17
02/22
12:01
02/22/17
12:01
Options
Newfield Exploration puts active as shares fall on earnings »

Newfield Exploration puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

11:59
02/22/17
02/22
11:59
02/22/17
11:59
Conference/Events
JPMorgan biotech/biopharma analysts hold an analyst/industry conference call »

SMid Biotech Analyst…

TWTR

Twitter

$16.33

-0.09 (-0.55%)

11:59
02/22/17
02/22
11:59
02/22/17
11:59
Hot Stocks
Twitter director of finance David Bicknell resigns »

David Bicknell, director…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 23

    Feb

  • 28

    Feb

  • 19

    Mar

PSX

Phillips 66

$78.29

-0.7425 (-0.94%)

11:56
02/22/17
02/22
11:56
02/22/17
11:56
Options
Phillips 66 put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLB

Dolby

11:54
02/22/17
02/22
11:54
02/22/17
11:54
Conference/Events
Dolby management to meet with William Blair »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 27

    Feb

  • 28

    Mar

TREX

Trex Company

$66.58

-4.57 (-6.42%)

11:53
02/22/17
02/22
11:53
02/22/17
11:53
Conference/Events
Trex Company management to meet with Stephens »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

P

Pandora

$13.08

-0.065 (-0.49%)

11:52
02/22/17
02/22
11:52
02/22/17
11:52
Conference/Events
Pandora management to meet with B. Riley »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

  • 28

    Feb

  • 19

    Mar

CARB

Carbonite

$19.65

0.05 (0.26%)

11:50
02/22/17
02/22
11:50
02/22/17
11:50
Conference/Events
Carbonite management to meet with Lake Street »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

  • 27

    Feb

RP

RealPage

$34.35

-0.2 (-0.58%)

11:50
02/22/17
02/22
11:50
02/22/17
11:50
Hot Stocks
RealPage announces new multi-year agreement with Morgan Properties »

RealPage announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.